Stock listing

CABA Stock Price, News, Filings & Events — Cabaletta Bio, Inc.

Selected listing: CABA · BMV · MXN · MX

This page tracks Cabaletta Bio, Inc.'s CABA:BMV listing on BMV in MXN for MX, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following CABA:BMV. CABA:BMV is the stock-level entry point for investors researching Cabaletta Bio, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Cabaletta Bio, Inc. is a public biotechnology company based in the United States, focused on developing innovative cell therapies for autoimmune diseases. The company is traded under the ticker symbol CABA and has a market capitalization of approximately $438.6 million. Cabaletta Bio is committed to advancing its research and development efforts in the field of immunotherapy.

CABA:BMVMXNMXUpdated August 31, 2026
Cabaletta Bio, Inc. logo
Ticker
CABA:BMV
Asset type
Stock
Market cap
$529.0M
Sector
Health Technology
Industry
Biotechnology
Exchange
BMV
Currency
MXN

Cabaletta Bio, Inc. CABA:BMV stock context

This page tracks Cabaletta Bio, Inc.'s CABA:BMV listing on BMV in MXN for MX, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following CABA:BMV. CABA:BMV is the stock-level entry point for investors researching Cabaletta Bio, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Cabaletta Bio, Inc. is a public biotechnology company based in the United States, focused on developing innovative cell therapies for autoimmune diseases. The company is traded under the ticker symbol CABA and has a market capitalization of approximately $438.6 million. Cabaletta Bio is committed to advancing its research and development efforts in the field of immunotherapy.

Latest news from Cabaletta Bio, Inc.

All Cabaletta Bio, Inc. news →

Cabaletta Bio, Inc. earnings calls

Research Cabaletta Bio, Inc.

Alternate listings